PLA2G2A and COVID-19: Indeed, sPLA2 acts as a prominent immune‐lipidomic hub, discriminates between moderate and severe sepsis in COVID‐19 and links eicosanoids to multiple inflammatory proteins and to clinical markers of disease severity.